Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-07

Clinical Trial Update: A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea

View source ↗

Summary

Post-marketing surveillance study on NesinaAct tablet use in Korean participants with Type 2 Diabetes Mellitus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nesinaact

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus | Status: COMPLETED | Results posted: 2022-03-07